Jake Martins
About Jake Martins
Jake Martins serves as the Associate Director at Kite Pharma in El Segundo, California, a position he has held since 2021. He earned his PhD in Biochemistry and Molecular Biology from the University of California, Los Angeles, and has extensive experience in quality control and management within the biopharmaceutical industry.
Work at Kite Pharma
Jake Martins has been serving as Associate Director at Kite Pharma since 2021. He is based in El Segundo, California, where he has contributed to the company's initiatives for three years. Prior to his current role, he worked as Senior Manager at Kite Pharma from 2018 to 2021 in Santa Monica, California. His experience at Kite Pharma encompasses various responsibilities that align with the company's focus on innovative cancer therapies.
Education and Expertise
Jake Martins earned his PhD in Biochemistry and Molecular Biology from the University of California, Los Angeles, where he studied from 2003 to 2010. His academic background also includes a Bachelor of Science in Biochemistry from the University of California, Davis, completed between 1994 and 1998. This educational foundation has equipped him with extensive knowledge in biochemical processes and molecular biology, essential for his roles in the pharmaceutical industry.
Background
Before joining Kite Pharma, Jake Martins held several managerial positions at Grifols. He worked as Manager of QC Chemistry from 2017 to 2018 and as Manager of QC Microbiology and Biology from 2013 to 2017. His tenure at Grifols provided him with valuable experience in quality control within the biopharmaceutical sector, enhancing his expertise in ensuring product safety and efficacy.
Professional Experience
Jake Martins has accumulated significant experience in the biopharmaceutical industry over the years. His career includes roles at Kite Pharma, where he progressed from Senior Manager to Associate Director, and at Grifols, where he managed quality control departments. This diverse experience has contributed to his understanding of both operational and strategic aspects of pharmaceutical development.